manufacturing, marketing and distribution of medicines, healthcare products and branded genericsProduct Profile: Company has an extensive basket of 50 Brands (125 products) with a portfolio contributing to 10 therapeutic areas, covering multiple dosage forms like Tablets, Capsules, Oral Liquids, Ointments and Injectables.
Gujarat Terce Laboratories has disclosed its financial results for the quarter ended June 30, 2025. The company reported net revenue from operations of Rs 11.88 crore. Including other income of Rs 0.07 crore, the company posted a net loss after tax of Rs 0.07 crore for the period. The Board...
Gujarat Terce Laboratories has shared its financial results and business update for the quarter. Revenue saw a 9% decline to ₹10.85 Cr, and EBITDA dropped by 51% to ₹0.07 Cr. However, the net loss decreased by 44% to ₹0.04 Cr, and cash profit surged by 255% to ₹0.05 Cr. The...
Gujarat Terce Laboratories Limited has informed shareholders about its upcoming 40th Annual General Meeting. The meeting will be held virtually via Video Conferencing/Other Audio Visual Means, allowing convenient participation. Shareholders can exercise their voting rights through a remote e-voting facility. The company's Register of Members and Share Transfer Books will...
Gujarat Terce Laboratories has confirmed it is not required to submit a Corporate Governance Report for the quarter ended June 30, 2025. This is due to the company's paid-up equity capital being consistently below 10 Cr and its net worth below 25 Cr. Specifically, for the past three financial years...
Gujarat Terce Laboratories Limited has announced a certificate from its registrar and transfer agent confirming that all securities received for dematerialization up to the quarter-end were processed and listed on the stock exchange. The physical certificates were verified, mutilated, and cancelled, with ownership records updated to reflect depository names within...
